Artificial tear preparations are important in the management of dry eye syndrome. We present the findings from four recently published studies conducted in Russia assessing Hylabak® (marketed as Hyabak® in Europe), a preservative-free hyaluronic acid preparation, for the treatment of dry eye syndrome. All studies had an open, noncomparative design, but one compared the findings with those from 25 patients treated with Tear Naturale® in previous studies. A total of 134 children and adults were enrolled, and the etiologies of dry eye syndrome included contact lens use, intensive office work, adenovirus eye infection, postmenopausal status, persistent meibomian blepharitis, Sjögren’s syndrome, phacoemulsification with intraocular lens implantation, and refractive surgery. The patients were treated with Hylabak for 2 weeks to 2 months. All studies showed that Hylabak resulted in marked improvement as assessed by subjective sensations/complaints, Schirmer’s test, Norn’s test, impression cytology and biomicroscopy, staining, and tear osmolarity. Greater benefits were also reported compared with Tear Naturale, including a faster onset of action. Hylabak was well tolerated. In conclusion, Hylabak provided rapid and safe relief from the signs and symptoms of dry eye syndrome, as well as improvement in objective measures, in a wide range of patients.
Pterygium is one of the modern problems of ophthalmology. The exact etiology and pathogenesis of this disease has not been reliably established and, as a result, there is no universal method for its recurrence-free treatment. The literature data on various methods of pterygium surgical treatment such as 'bare sclera', conjunctival autograft, limbal stem cells transplantation techniques, amniotic membrane plasty and other methods was analyzed. The advantages and disadvantages of those surgery methods were identified. With consideration of the new data on proliferative nature of the disease, the results of adjuvant treatment of pterygium using cytostatics and anti-VEGF drugs were examined. Introduction of new technologies for the treatment of pterygium in practical health care can significantly improve the effectiveness of surgeries, reduce the incidence of postoperative complications and the number of relapses of the disease.
The article presents an analysis of literature data on the changes in structure and frequency of eye injuries among the adult population of the Russian Federation over the recent years. An estimation of various socio-economic and medical factors influencing these indicators was derived. The article also reviews current methods of treatment of eye injuries, and provides an evaluation of their effectiveness.
ООО «Медицинская клиника ЛиконтЮг» ул. Рионская 4, г. Волгоград, 4000107, Российская Федерация резЮме цель: проведение клинического мониторинга функциональных показателей у пациентов с ранней стадией возрастной макулярной дегенерации (ВМД) на фоне приема биологически активной добавки (БАД) к пище «Ретинорм». Пациенты и методы. Клинический мониторинг проводился в течение 5 месяцев у 40 пациентов в возрасте 42-75 лет с ранней стадией ВМД. Основными проявлениями ВМД были сухие друзы и дефекты пигментного эпителия в виде «географической атрофии». Помимо ВМД, у всех пациентов имела место катаракта в начальной стадии. Основная группа (20 человек, 35 глаз) в качестве трофической терапии получала БАД «Ретинорм» по 1 капсуле 3 раза в день-прием 2 месяца, перерыв 1 месяц, продолжение приема в течение 2-х месяцев. Вместе с приемом Ретинорма пациенты получали инстилляции Визомитина® 3 раза в день следующим курсом: инстилляции 2 месяца, перерыв 1 месяц, продолжение инстилляций в течение 2-х месяцев. Контрольная группа (20 человек, 34 глаза) получала только Визомитин® в инстилляциях 3 раза в день аналогично группе наблюдения. В качестве методов мониторинга были использованы визометрия с коррекцией, компьютерная статическая периметрия, оптическая когерентная томография центральной области глазного дна, определение КЧСМ, электрической чувствительности сетчатки и лабильности зрительного нерва. результаты. В основной группе терапия привела к повышению как некорригированной, так и максимальной корригированной остроты зрения, уменьшению числа относительных скотом в центральной области поля зрения, повышению КЧСМ (p<0,05) и определила тенденцию к повышению электрической лабильности (p<0,5) и снижению порога электрической чувствительности сетчатки (p<0,2). У пациентов контрольной группы положительная динамика мониторируемых показателей оказалась несущественной и недостоверной. заключение. Полученные данные свидетельствуют о положительном влиянии Ретинорма на состояние фоторецепторного аппарата сетчатки и на метаболизм хрусталиковой линзы, что способствует стабилизации патологического процесса при ВМД и начальной возрастной катаракте. БАД «Ретинорм» может быть рекомендован для широкого применения у пациентов с ВМД в ранней стадии при возможной ассоциации с начальной сенильной катарактой. ключевые слова: возрастная макулярная дегенерация, ранняя стадия, начальная катаракта, Ретинорм, Визомитин®, зрительные функции, электрофизиологические показатели, толщина сетчатки в центральной области для цитирования:
PURPOSE. To improve the effectiveness of primary angle closure glaucoma (PACG) treatment in the initial stage in patients with hyperopia.MATERIAL AND METHODS. The study observed 18 patients (36 eyes) with the initial stage of PACG who also had low (8 subjects, 16 eyes) or moderate (10 subjects, 20 eyes) hyperopia. Study patients were divided into two groups: the main group — 12 patients (24 eyes) aged 43–67 years (mean age 55.6±1.1 years); the control group — 6 patients (12 eyes) aged 48–60 years (mean age 56.4±2.4 years). Prescribed treatment in the main group: selection and application of universal progressive correction, then laser iridecotomy (LIE) and management without pilocarpine instillations. Prescribed treatment in the control group: selection and application of monofocal correction for near vision, then LIE and instillations of 1% pilocarpine solution 3 times a day. All patients underwent visometry with correction, refractometry, ophthalmoscopy, tonometry, tonography, gonio-scopy, optical coherence tomography of the anterior eye segment, ultrasound biometry. Indicators of hydrodynamics and parameters of the anterior chamber were recorded before using spectacles correction, after the start of correction, after LIE, and 1 month after the start of all therapeutic measures.RESULTS. The use of progressive spectacle correction led to a significant decrease of true intraocular pressure (IOP) (p<0.001), an improvement of aqueous humor outflow (p<0.05) and an increase in the size of anterior chamber angle (p<0.001). Performing LIE in patients of the main group did not significantly change these indicators. The results obtained in this group made it possible to abandon the use of pilocarpine. In patients of the control group, the improvement in aqueous humor outflow (p<0.001) and increase in the size of anterior chamber angle (p<0.002) were more significant after LIE than after prescription of adequate monofocal correction for near vision (p<0.02–0.05 and p<0.2, respectively).CONCLUSION. The use of progressive spectacle correction in patients with hyperopia and initial stage of PACG before LIE leads to normalization of hydrodynamic parameters and an increase in the magnitude of anterior chamber angle without the use of miotic drugs. Prescription of progressive spectacle correction is advisable in these patients as a part of the complex of therapeutic measures aimed at normalizing ocular hydrodynamics.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.